Navigation Links
ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
Date:10/30/2008

- Conference Call to Be Held at 4:00 P.M. Eastern Time -

EXTON, Pa., Oct. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) will host a conference call and live audio webcast at 4:00 p.m. Eastern Time on Wednesday, November 5, 2008 to discuss the commercialization plans and launch of Cinryze C1 Inhibitor (human), which has been recently approved by the U.S. Food and Drug Administration for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.

The live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 20, 2008. To participate in the conference call, please dial (877) 366-0713 (domestic) and (302) 607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing infor
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
2. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
3. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
5. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
6. ViroPharma Provides Update on Vancocin(R)
7. ViroPharma Augments Senior Management
8. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
9. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
10. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
11. ViroPharma to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... According to the Greek God Muscle Building Program review ... that teaches men how to completely transform their physique by ... its review that inside the Greek God Muscle Building Program ... gain the maximum muscle fiber recovery , ... gain , Ways to incorporate the specialization routines ...
(Date:7/28/2014)... 28, 2014 To commemorate World Hepatitis ... of Living with a Disability magazine has ... disorders that include hepatitis, gastrointestinal hemorrhage, inflammatory bowel disease, ... important new article highlights that, in the context of ... hepatitis and other disabling conditions related to the digestive ...
(Date:7/28/2014)... 28, 2014 Greta Pontarelli, 63, won her ... Champion title at the World Pole Sports Championships in London ... this athlete. She is the only U.S. competitor to qualify, ... Pole Sports Federation (IPSF). Over 150 athletes ranging in age ... in the competition. Pontarelli scored first place in the Masters ...
(Date:7/27/2014)... 28, 2014 Zensah®, the leader in compression ... include a wrist support . The wrist support features ... area. , Lateral and Medial Epicondylitis, more commonly referred to ... which there is inflammation of the tendons attached to the ... wrist pain, the muscles that work the wrist and fingers ...
(Date:7/27/2014)... regimens could provide shorter, more effective treatment options with ... with hepatitis C, even those most difficult to treat, ... The Lancet . , Both studies focused on ... genotype in the USA, Europe, North Asia, Australia, and ... treat. , Around 150 million people worldwide have chronic ...
Breaking Medicine News(10 mins):Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:Zensah® Releases New Wrist Support 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it ... 5, 2009. In conjunction, the Company will host a conference call at ... update. , , Date: ... Conference call access:, Internet: www.istavision.com, ...
... KALAMAZOO, Mich., July 29 Stryker Corporation (NYSE: ... Directors to nine and the election of Dr. Srikant M. Datar as ... Associate Dean and Director of Research at the Graduate School of Business ... at Harvard University since joining that organization in 1996. , , ...
... , , , , ... a worldwide leader in the development, distribution and use of ... $5 million financing commitment from Toronto-based MMV Financial ("MMV"). ... on-going cutting-edge clinical research, including immunotherapy and focal therapy, for ...
... ... of being overbilled, double-billed or billed for expenses they didn,t incur. , ... Norwalk, CT (PRWEB) July 29, 2009 -- ccording ... role in fully half of all U.S. foreclosures. CreditFYI, an educational consumer website on ...
... , , NEW YORK, July ... Cristie Kerr in 2003 with a mission to raise funds and ... classic will be held at Liberty National. The event, on Friday, ... a dinner reception and poker tournament. Renowned celebrity chef Todd ...
... North Carolina are reporting assembly of the first functioning ... inside cells helps process and package hormones, enzymes, and ... The lab-on-a-chip device could lead to a faster and ... or blood thinner, the researchers note. Their study is ...
Cached Medicine News:Health News:Stryker Announces Election of New Director 2Health News:US HIFU Secures $5 Million Financing From MMV Financial 2Health News:US HIFU Secures $5 Million Financing From MMV Financial 3Health News:As Medical Bills Contribute to 50% of U.S. Foreclosures, CreditFYI Shares 5 Tactics for Managing Medical Debt 2Health News:Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Women's Golfer, Cristie Kerr 2
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... of Powers Lake, Wisconsin , ... a distribution and co-marketing agreement allowing ScriptPro to ... throughout the United States . ... management and workflow systems to retail and ambulatory ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
Breaking Medicine Technology:Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... Filtrona Porous Technologies, a custom developer and manufacturer ... to absorb, retain, transfer, filter or release fluids ... polyurethane foams and bonded fibers at the MEDICA ... 17 to 19 November 2010. ...
... Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics ... Moch, President and Chief Executive Officer, will present at ... Wednesday, November 17, 2010, 10:30 a.m. ET, at the ... Mr. Moch will give an update on the company,s ...
Cached Medicine Technology:Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2
Flattened points in vertical plane, straight shafts, cross action, round handle....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Round serrated handle, dull finish....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Medicine Products: